Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

4 Jan 2021

Abstract excerpt

Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical and molecular features of HER2-low BC are yet to be elucidated. Here, we collected retrospective clinicopathological and PAM50 data from 3,689 patients with HER2-negative disease and made the following...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Cancer Treatment Studies
Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33397968
DOI: 10.1038/s41523-020-00208-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancerPMID 33397968Read ↗

Clinicopathological features and prognosis of HER2 low-expression breast cancer: a single-center retrospective studySemantic proximity Read ↗

Molecular and clinical traits of HER2-low breast cancer patients and their relationship with neoadjuvant treatment effectiveness.Semantic proximity Read ↗

A gene expression-based classifier for HER2-low breast cancerSemantic proximity Read ↗

Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas.Semantic proximity Read ↗

Do HER2-Low Tumors Have a Distinct Clinicopathologic Phenotype?Semantic proximity Read ↗

[Biological characteristics of triple negative breast cancer with low expression of HER2].Semantic proximity Read ↗

Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other BiomarkersSemantic proximity Read ↗

HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast CancerSemantic proximity Read ↗

Clinical Significance and Genetic Characteristics in HER2 Low Expression Tumors of Hormone Receptor Positive Breast Cancer PatientsSemantic proximity Read ↗

Exploring the Heterogeneity of HER2 gene status and Expression in Non-Positive Breast Cancer Patients: Insights from Immunohistochemistry and Fluorescence In Situ HybridizationSemantic proximity Read ↗

Molecular and Clinical Portrait of HER2-low Invasive Lobular Carcinomas.Semantic proximity Read ↗

Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.